Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal

In this phase 3, randomized, controlled trial, children in Nepal between 9 months and 16 years of age received either a typhoid conjugate vaccine (TCV) (n =10,005) or a capsular group A meningococcal conjugate vaccine (MenA) (n = 10,014) as a control. Primary outcome was typhoid fever confirmed by blood culture. Typhoid fever occurred in 7 participants who received TCV and 38 who received MenA vaccine (vaccine efficacy, 81.6%; 95% confidence interval, 58.8 to 91.8; P < 0.001).

To read the full article, visit the New England Journal of Medicine.